HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
ID: 343213Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $750K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/343213

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-002.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity under the HEAL Initiative for the translational development of diagnostic and therapeutic devices aimed at treating pain and opioid use disorder (OUD). This initiative seeks proposals for the creation of clinical-grade prototypes that utilize safe, effective, and non-addictive technologies, with a focus on overcoming challenges identified in preliminary studies to prepare for first-in-human clinical trials. The program is critical in addressing the national opioid crisis by fostering innovation in treatment alternatives, with approximately $6 million available for 8-12 awards in fiscal year 2023. Interested applicants, including various academic institutions and community organizations, must submit proposals by June 17, 2025, and can find further details and application instructions at the NIH grants website or by contacting grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-EB-22-002-Full-Announcement.html
    RFA-EB-22-002.html
    The Department of Health and Human Services, through the NIH HEAL Initiative, is seeking proposals for the development of clinical-grade devices aimed at diagnosing and treating pain and opioid use disorder (OUD). This initiative aligns with a broader effort to combat the national opioid crisis by fostering innovation in safe, effective, and non-addictive treatment alternatives. Eligible applicants can include various academic institutions, nonprofits, and governmental organizations, with a funding commitment of approximately $6 million for 8-12 awards in fiscal year 2023. Projects must demonstrate a clear path towards clinical application within five years and provide evidence of safety and effectiveness through preclinical studies. Applicants are encouraged to leverage existing technologies, engage diverse teams, and actively plan for future commercialization. Important submission details include adherence to rigorous instructions, use of specific application forms, and timely registration with required systems. The proposal review will prioritize significance, investigator competence, innovation, approach, and environment, ultimately aiming to enhance the translation of novel technologies for treating pain and OUD into clinical practice.
    Similar Opportunities
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems." This initiative aims to develop strategies to enhance the sustainable and effective delivery of integrated care for individuals suffering from both chronic pain and OUD, addressing barriers at the health systems level. The importance of this opportunity lies in its focus on improving collaborative care models and implementation strategies to better manage these co-occurring conditions, which affect a significant portion of the population. Interested applicants, particularly small businesses with expertise in chronic pain management and OUD, are encouraged to prepare for the application process, with the estimated synopsis post date set for January 12, 2026, and the estimated award date anticipated for April 1, 2027. For further inquiries, potential applicants can contact Shelley Su, Ph.D., at IMPOWR@nih.gov or by phone at 301-402-3869.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative for the development of non-addictive analgesic therapeutics, specifically targeting small molecules and biologics to treat pain. This cooperative agreement aims to accelerate the discovery and optimization of promising therapeutic candidates, facilitating their readiness for Phase II clinical studies, while excluding basic research and clinical studies beyond Phase I. The program encourages collaborations among researchers with expertise in pain therapeutics development, with applications expected to be submitted by early 2026, and an estimated award date set for September 2026. For further inquiries, interested parties can contact Dr. Mohamed Hachicha at 301-496-1779 or via email at mohamed.hachicha@nih.gov.
    HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the HEAL Initiative: Pain Management Effectiveness Research Network, specifically for Clinical Trial Planning and Implementation through a Cooperative Agreement (UG3/UH3). This initiative aims to conduct large-scale, multisite clinical trials that will evaluate the efficacy of interventions designed to reduce opioid use and improve pain management across various conditions, thereby enhancing functional outcomes for patients suffering from acute to chronic pain. The program is critical in expanding evidence-based therapeutic options for pain relief, benefiting patients and their families. Interested applicants, including various eligible entities such as tribal governments and community organizations, are encouraged to prepare for this opportunity, with applications expected to be solicited starting October 15, 2025, and closing on January 5, 2026. For further inquiries, potential applicants can contact Dr. Yolanda F. Vallejo at 301-451-1751 or via email at Yolanda.Vallejo@nih.gov.
    HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity under the HEAL Initiative, aimed at enhancing the implementation and sustainability of substance use preventive services. This initiative seeks to address the critical gaps between effective prevention research and its practical application, particularly in combating the opioid crisis, by soliciting applications for projects that demonstrate preliminary data and focus on strengthening prevention infrastructure. With approximately $4.65 million available for funding, grants can support projects for up to five years, with annual budget requests advised to remain under $800,000. Interested applicants must submit their proposals by January 16, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center." This initiative aims to address the co-occurrence of chronic pain (CP) and opioid use disorder (OUD) by testing implementation strategies and collaborative care models to enhance the integration of services across diverse health settings. The program is critical for improving treatment outcomes for individuals affected by both conditions, as effective management is often hindered by fragmented healthcare systems. The estimated total funding for this program is $1,750,000, with one award expected to be made. Interested applicants can reach out to Dr. Shelley Su at IMPOWR@nih.gov or by phone at 301-402-3869 for further information. The estimated synopsis post date is January 12, 2026, with applications expected to close on November 2, 2026, and awards anticipated by April 1, 2027.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to release a Notice of Funding Opportunity (NOFO) titled "HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)" aimed at supporting research that translates addiction-related findings into practical applications to combat the opioid crisis and overdose events. This initiative seeks to identify and address factors influencing substance use and overdose deaths, focusing on developing effective, scalable interventions that integrate evidence-based practices into routine healthcare. Interested small businesses are encouraged to prepare for this opportunity, with applications expected to be solicited after the estimated synopsis post date of August 1, 2025, and closing on October 16, 2025. For further inquiries, potential applicants can contact Dr. Tisha Wiley at tisha.wiley@nih.gov or by phone at 301-594-4381.